Group 1: A-share New IPOs - Two new stocks available for subscription next week: Aishalon and Hengyunchang, with subscription dates on January 12 and January 16 respectively [1] - Aishalon, a leading company in the medical dressing sector, has an issue price of 15.98 yuan per share and an issuance PE ratio of 14.99, compared to the industry average of 29.79 [1] - Aishalon plans to issue a total of 16.92 million shares, with 15.23 million shares available for online subscription, and a maximum subscription limit of 761,300 shares per investor [1] Group 2: Aishalon Financial Performance - Aishalon's projected revenues for 2022 to 2025 are 574 million yuan, 575 million yuan, 692 million yuan, and 438 million yuan respectively, with net profits of 62.8 million yuan, 66.96 million yuan, 80.71 million yuan, and 49.68 million yuan [2] - For 2025, Aishalon expects revenues between 890 million yuan and 940 million yuan, representing a year-on-year growth of 28.65% to 35.89%, and net profits between 89.29 million yuan and 98.48 million yuan, with a growth of 10.63% to 22.01% [4][5] Group 3: Hengyunchang Overview - Hengyunchang is a core component supplier for semiconductor equipment, focusing on the research, production, and sales of plasma RF power systems and related components [6] - The company has been recognized as a national-level "specialized and innovative" small giant, filling a gap in domestic plasma RF power systems for high-end semiconductor applications [7] - Hengyunchang has achieved significant market share, ranking first among domestic plasma RF power system manufacturers in China [7] Group 4: Hengyunchang Financial Performance - Hengyunchang's revenues for 2022 to 2025 are projected at 158 million yuan, 325 million yuan, 541 million yuan, and 304 million yuan respectively, with net profits of 26.19 million yuan, 79.83 million yuan, 142 million yuan, and 69.35 million yuan [7] - For 2025, Hengyunchang anticipates revenues between 489 million yuan and 515 million yuan, reflecting a decline of 9.58% to 4.69% year-on-year, and net profits between 102 million yuan and 114 million yuan, with a decrease of 28.21% to 19.54% [10][12]

Group 1 - Jiangsu Aisheren Medical Technology Group Co., Ltd. officially listed on the Beijing Stock Exchange on January 21, 2026, marking it as the first A-share listed company in Jiangsu Province and the first company from Xiangcheng to be listed on the Beijing Stock Exchange [1] - The IPO involved the issuance of 16.9198 million shares at a price of 15.98 yuan per share, raising a total of 270 million yuan, primarily for the construction of the Kaipule Public Health Medical Supplies Industrial Park [1] - Aisheren specializes in disposable medical consumables and ranks among the top ten exporters of padding medical dressings in China, supported by nearly 80 patents and a network of nine factories globally, exporting to over 50 countries [1] Group 2 - Xiangcheng District emphasizes the importance of corporate listings and actively supports companies in their listing efforts, providing real-time solutions and policies to meet corporate needs [1] - The district has implemented the "Seedling Plan" and established a "five-tier" cultivation model to enhance the connection between enterprises and the capital market, holding various meetings to coordinate essential resources for companies [1] - As of now, there are 20 listed companies in the district, with a total market value of approximately 130 billion yuan [1]

Core Viewpoint - Gongdong Medical (605369) has announced a significant decline in its expected net profit for 2025, forecasting a drop of 67.37% to 74.36% year-on-year, with net profit projected between 44 million to 56 million yuan [4]. Financial Performance - The expected non-recurring net profit for 2025 is estimated to be between 54 million to 66 million yuan, reflecting a year-on-year decrease of 60.75% to 67.89% [4]. - As of January 23, the company's price-to-earnings ratio (TTM) is approximately 77.37 to 98.47 times, with a price-to-book ratio (LF) of about 2.52 times and a price-to-sales ratio (TTM) of around 3.85 times [4]. Reasons for Performance Decline - The decline in performance is attributed to several factors: 1. **Goodwill Impairment**: The company has recognized signs of impairment related to goodwill from its acquisition of Trademark Plastics Inc. (TPI), with an estimated impairment amount between 24 million to 30 million yuan due to TPI's operational challenges influenced by international trade policies and shipping cost fluctuations [13]. 2. **Gross Margin Decrease**: The gross margin has been affected by the slowdown in demand for certain products due to U.S. tariff policies and domestic medical procurement policies [14]. 3. **Exchange Rate Fluctuations**: Financial expenses related to exchange rate fluctuations have significantly reduced, contributing to the decline in net profit. Additionally, losses from investments in a controlled entity have impacted non-operating income by approximately 11 million yuan [15].

Group 1 - Aisheren (920050) experienced a significant increase of 175.59% on its first trading day, with a turnover rate of 78.23% and a transaction volume of 689 million yuan [2] - The stock's first-day margin trading saw a buy amount of 7.65 million yuan, accounting for 1.11% of the total trading volume, with a latest margin balance of 7.24 million yuan, representing 0.91% of the circulating market value [2] - The company focuses on the healthcare sector, primarily engaged in the research, production, and sales of disposable medical consumables used in professional rehabilitation care and medical protection, providing products for internationally renowned medical device brands through ODM/OEM methods [2] Group 2 - Recent IPOs have shown varying first-day performance, with Kema Materials (920086) rising by 371.27%, and Zhixin Stock (603352) increasing by 213.44% on their respective debut days [3] - The first-day margin balances for other recent IPOs include 7.49 million yuan for Kema Materials, which is 0.72% of its circulating market value, and 82.41 million yuan for Zhixin Stock, accounting for 2.71% [3] - The data indicates a trend of high volatility and investor interest in newly listed stocks, as evidenced by the substantial price increases and high turnover rates [3]

（文章来源：证券时报网） 2022年度至2025年1-6月，爱舍伦主营业务收入分别为5.72亿元、5.72亿元、6.89亿元及4.36亿元，最近 三年收入复合增长率为9.73%，收入稳步增长。公司主营业务收入主要来源于境外销售。报告期各期， 公司境外销售收入分别为5.2亿元、5.39亿元、6.52亿元和4.21亿元，占当期主营业务收入比例分别为 90.99%、94.25%、94.71%和96.54%，境外销售收入占比较高，公司产品主要销往美国、欧洲、韩国等 国家和地区。 结合目前的订单情况、经营状况以及市场环境，爱舍伦预计2025年度营业收入约为8.90亿元至9.40亿 元，同比增长幅度约为28.65%至35.89%，主要系下游需求增加及公司产能扩大，公司业务规模扩大； 归属于母公司所有者的净利润约为8929.26万至9847.74万元，同比增长幅度约为10.63%—22.01%;归属于 母公司所有者的扣除非经常性损益后的净利润约为8610.78至9529.27万元，同比增长幅度约为19.37%至 32.11%。 通过此次成功发行及募投项目的陆续实施，爱舍伦将进一步提升现有产品产能，加大新型医用耗材研发 投入 ...

Core Viewpoint - Aishalon Medical Technology Group Co., Ltd. (stock code: 920050.BJ) was listed on the Beijing Stock Exchange, opening at 48.88 yuan and closing at 44.04 yuan, with a significant increase of 175.59% and a total market capitalization of 2.981 billion yuan [1]. Company Overview - Aishalon focuses on the medical health sector, primarily engaged in the research, production, and sales of disposable medical consumables for rehabilitation care and medical protection [1]. - The company provides products to internationally renowned medical device brands through ODM/OEM methods [1]. Shareholding Structure - The controlling shareholder is Jiangsu Novick Technology Investment Co., Ltd., with Zhang Yong as the actual controller, holding a total of 88.69% of the company's shares [1][2]. - After the issuance, Zhang Yong directly holds 1,000,000 shares (1.48%) and indirectly controls 45,017,025 shares (66.52%) [2]. Financial Performance - In 2022, 2023, and 2024, Aishalon's revenue was 573.56 million yuan, 574.66 million yuan, and 691.64 million yuan, respectively, with net profits of 62.80 million yuan, 66.94 million yuan, and 80.61 million yuan [7]. - For the first half of 2025, the revenue was 438.20 million yuan, with a net profit of 49.43 million yuan [8]. - The company reported a revenue of 68.96 million yuan for the first nine months of 2025, a year-on-year increase of 42.84%, and a net profit of 7.31 million yuan, up 26.98% [11]. Fundraising and Investment Projects - Aishalon raised a total of 270.38 million yuan, with a net amount of 240.18 million yuan allocated for the construction of the Caprol Public Health Medical Supplies Industrial Park [5]. - The total investment for the Caprol project is 670.46 million yuan, with 300 million yuan funded through this issuance [6]. Future Projections - The company expects 2025 revenue to be between 889.82 million yuan and 939.87 million yuan, representing a growth of 28.65% to 35.89% compared to 2024 [12]. - The projected net profit for 2025 is estimated to be between 89.29 million yuan and 98.48 million yuan, indicating a growth of 10.63% to 22.01% [12].

Core Viewpoint - Jiangsu Aisheren Medical Technology Group Co., Ltd. successfully went public on the Beijing Stock Exchange, becoming the first A-share listed company in Jiangsu Province this year and the first in Suzhou's Xiangcheng District on the North Exchange [1][6]. Company Overview - Aisheren focuses on the medical health sector, primarily engaged in the research, production, and sales of disposable medical consumables used in rehabilitation care and medical protection [3][8]. - The company provides products through ODM/OEM methods for internationally renowned medical device brands, continuously expanding its product line to include disinfection, home protection, and emergency protection [3][9]. - Aisheren has obtained several certifications, including ISO13485:2016, EU CE certification, and US FDA registration, meeting high global standards for medical consumables [3][9]. Future Plans - The successful IPO will serve as a catalyst for Aisheren to enhance existing production capacity and increase investment in the research and development of new medical consumables [3][9]. - The company aims to actively expand its sterilization business and continuously optimize product quality and service levels [3][9]. - Aisheren plans to leverage the Belt and Road Initiative to deepen its presence in the global medical dressing market, contributing more Chinese wisdom and strength to global healthcare [3][9]. Role of Dongwu Securities - Dongwu Securities acted as the sponsor and underwriter for Aisheren's IPO, showcasing its expertise in the medical consumables sector and enhancing its brand influence in the North Exchange [5][11]. - The firm has successfully sponsored and underwritten 48 companies in Suzhou, with a nearly 50% market share of Suzhou companies listed on the North Exchange [5][11]. - Dongwu Securities aims to continue its commitment to high-quality development and to advance towards becoming a leading investment bank characterized by specialization, market orientation, technological advancement, and internationalization [5][11].

Group 1: Market Overview - The A-share market experienced an overall upward trend on January 21, with major indices rising to varying degrees, particularly the electronic sector which saw a surge in limit-up stocks [1][2][5] - The ChiNext Index rose over 1.5%, while the Sci-Tech 50 Index increased by more than 4% during the trading session [2] Group 2: Electronic Sector Performance - The electronic sector led the market with a gain of over 2.8%, with multiple stocks hitting the daily limit-up [5] - Notable stocks included Longxin Technology and Zhongrong Electric, both achieving a limit-up of 20%, while several others like Kexiang Co. and Jiehuate saw increases exceeding 10% [5][6] Group 3: Stock Performance Data - Key stock performance data includes: - Longxin Technology (688047) at 177.72, up 20.00% with a trading volume of 2.075 billion - Zhongrong Electric (301031) at 143.40, up 20.00% with a trading volume of 687 million - Other significant gainers included Haiguang Information (688041) up 12.40% and Dagan Co. (002077) up 10.03% [6] Group 4: Lithium Sector Activity - The lithium mining sector also saw significant gains, with the sector rising over 2% and stocks like Dazhong Mining and Weicheng Mining hitting the daily limit-up [7] - The surge was attributed to a notable increase in domestic lithium carbonate futures, with the main contract rising over 6% [7] Group 5: New Stock Listing - A new stock, Aisheren, debuted on the A-share market with an impressive rise of over 200% during its trading session [9] - Aisheren focuses on the medical health sector, specializing in the development, production, and sales of disposable medical supplies for rehabilitation and medical protection [11] Group 6: Hong Kong Market Highlights - In the Hong Kong market, Skyworth Group saw a significant increase, with its stock price rising over 40% during the trading session [12] - The company announced plans for a distribution and listing of its solar subsidiary, Skyworth Solar, contingent on meeting certain conditions [14][15]

Group 1 - Aishalon (920050) has been listed on the Beijing Stock Exchange, focusing on the medical health sector, specifically in the research, production, and sales of disposable medical consumables for rehabilitation care and medical protection [1] - The company is controlled by Jiangsu Novik Technology Investment Co., Ltd., with Zhang Yong as the actual controller, holding a total of 88.69% of the company's equity [1] - After the issuance, Zhang Yong directly holds 1,000,000 shares (1.48%) and indirectly holds 40,394,700 shares (59.69%) through Jiangsu Novik, along with additional shares through partnerships, totaling 45,017,025 shares (66.52%) of voting rights [2] Group 2 - The total amount raised from the issuance is 270.38 million yuan, with a net amount of 240.18 million yuan after deducting non-tax issuance costs, which will be used for the construction of the Caple Public Health Medical Supplies Industrial Park project [2]

Group 1: Company Overview of Meidel - Meidel, established in 2009, is a leading supplier of intelligent conveyor systems in China, focusing on the research, design, manufacturing, and sales of smart manufacturing equipment, particularly modular conveyor systems and industrial components [2][5] - The company’s products are integral to factory automation and are widely used in industries such as new energy, automotive parts, electronics, and warehousing logistics [5] - As of September 30, 2025, Meidel holds 201 patents, including 21 domestic invention patents and 159 utility model patents, and is recognized as a national high-tech enterprise [5] Group 2: Financial Metrics and Market Position of Meidel - Meidel's IPO price is set at 41.88 yuan per share, with an issuance price-to-earnings ratio of 14.99, compared to the industry average of 47.36 [3] - The company’s revenue and net profit for 2022 are projected to show a growth rate of 15% and 10% respectively, with a forecasted decline of 10% in 2024 [3][6] - The company plans to allocate 1.20 billion yuan (18.60%) to the Dalian Meidel Phase IV construction project and 2.00 billion yuan (31.01%) to the development of high-end intelligent conveyor systems [4] Group 3: Customer Base and Risks of Meidel - Meidel has a high customer concentration risk, with sales to the top five customers accounting for 59.34% of total revenue in 2022, which is projected to rise to 62.75% by mid-2025 [6] - The concentration is attributed to the high market concentration in the new energy battery sector, where leading companies have significant demand for conveyor systems [6] Group 4: Company Overview of Aishalon - Aishalon, founded in 2003, specializes in the research, production, and sales of disposable medical consumables in the rehabilitation and medical protection fields [7][11] - The company is recognized as the largest manufacturer of medical care pads in China and is rapidly advancing towards the top four in the industry [11] Group 5: Financial Metrics and Market Position of Aishalon - Aishalon's IPO price is set at 15.98 yuan per share, with an issuance price-to-earnings ratio of 14.99, compared to the industry average of 29.79 [8] - The company plans to invest 3.00 billion yuan (100%) into the Caprol public health medical supplies industrial park construction project [10] Group 6: Customer Base and Risks of Aishalon - Aishalon faces a high customer concentration risk, with sales to the top five customers making up 81.99% of total revenue in 2022, increasing to 88.40% by mid-2025 [12] - The primary customer, Medline Group, represents a significant portion of sales, with its share ranging from 71.51% to 77.73% over the forecast period [12]